Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients

Aim To evaluate the safety and efficacy of transcatheter arterial chemo-lipiodol infusion (TACL) in high-risk patients with unresectable hepatocellular carcinoma (HCC). Materials and methods From January 2005 to April 2009, 96 patients underwent TACL. All patients had diffuse, infiltrative or multif...

Full description

Saved in:
Bibliographic Details
Published in:Clinical radiology 2010-04, Vol.65 (4), p.271-277
Main Authors: Yoon, H.-J, Kim, J.H, Kim, K.-A, Lee, I.-S, Ko, G.-Y, Song, H.-Y, Gwon, D.I
Format: Article
Language:English
Subjects:
Adult
Aged
Bilirubin - blood
Biological and medical sciences
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - therapy
Chemoembolization, Therapeutic - adverse effects
Chemoembolization, Therapeutic - methods
Chemoembolization, Therapeutic - mortality
Contrast Media - therapeutic use
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Infusions, Intra-Arterial
Iodized Oil - therapeutic use
Liver Neoplasms - mortality
Liver Neoplasms - therapy
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Radiology
Risk Factors
Serum Albumin - chemistry
Survival Rate
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To evaluate the safety and efficacy of transcatheter arterial chemo-lipiodol infusion (TACL) in high-risk patients with unresectable hepatocellular carcinoma (HCC). Materials and methods From January 2005 to April 2009, 96 patients underwent TACL. All patients had diffuse, infiltrative or multifocal tumours. Twenty-nine (30%) patients had an increased serum bilirubin level (≥2 mg/dl), and 75 patients (78%) had a low serum albumin level (
ISSN:0009-9260
1365-229X
DOI:10.1016/j.crad.2010.01.018